These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution. Lin TK; Yeh TH; Hsu PW; Chuang CC; Tu PH; Chen PY; Jung SM; Wei KC; Huang YC World Neurosurg; 2017 Jul; 103():550-556. PubMed ID: 28363832 [TBL] [Abstract][Full Text] [Related]
3. Central Nervous System Lymphoma. Chukwueke UN; Nayak L Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157 [TBL] [Abstract][Full Text] [Related]
4. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348 [TBL] [Abstract][Full Text] [Related]
5. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome. Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity. Song KW; Batchelor T Curr Oncol Rep; 2021 Sep; 23(11):132. PubMed ID: 34524547 [TBL] [Abstract][Full Text] [Related]
7. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Sethi TK; Reddy NM Leuk Lymphoma; 2019 Jan; 60(1):6-18. PubMed ID: 29741421 [TBL] [Abstract][Full Text] [Related]
9. Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature. Galarza Fortuna GM; Dvir K; Febres-Aldana C; Schwartz M; Medina AM J Investig Med High Impact Case Rep; 2019; 7():2324709619893548. PubMed ID: 31818145 [TBL] [Abstract][Full Text] [Related]
10. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986 [TBL] [Abstract][Full Text] [Related]
11. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. Biswas A; Adhikari N; Bakhshi S; Gopinathan VR; Sharma MC Pediatr Neurosurg; 2019; 54(1):57-65. PubMed ID: 30669145 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
13. Treatment of primary central nervous system lymphoma. Ekenel M; DeAngelis LM Curr Neurol Neurosci Rep; 2007 May; 7(3):191-9. PubMed ID: 17488584 [TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380 [TBL] [Abstract][Full Text] [Related]
16. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. Fleury I; Amorim S; Mounier N; Coiffier B; Dupuis J; Tilly H; Mazari MA; Filliatre L; Brière J; Brice P; de Kerviler E; Thieblemont C Leuk Lymphoma; 2015 Jul; 56(7):2025-31. PubMed ID: 25347431 [TBL] [Abstract][Full Text] [Related]
17. New approaches in primary central nervous system lymphoma. Fraser E; Gruenberg K; Rubenstein JL Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700 [TBL] [Abstract][Full Text] [Related]
20. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma. Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]